Ascending single-dose study of the safety, pharmacokinetics, and pharmacodynamics of CSTI-500, a novel monoamine triple reuptake inhibitor, first-in-human.
Rationale: Monoamine triple reuptake inhibitors (TRIs) inhibit central dopamine, norepinephrine, and serotonin transporters, restoring functional monoamine neurotransmission. Objectives: This clinical trial evaluated the safety, tolerability, and pharmacokinetics in healthy volunteers after single-a...
| Publicado en: | Psychopharmacology Vol. 243; no. 3; pp. 565 - 581 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Mar2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |